Aptevo Therapeutics (APVO) Cost of Revenue (2015 - 2019)

Aptevo Therapeutics has reported Cost of Revenue for 5 years, with the latest figure at $6.1 million in Q4 2019.

• Quarterly Cost of Revenue changed N/A year-over-year to $6.1 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $19.9 million (changed N/A YoY) and the FY2019 annual result came in at $19.9 million, up 77.7% from the prior year.
• Cost of Revenue grew to $6.1 million in Q4 2019 per APVO's latest filing, from $4.0 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $6.8 million in Q3 2018 and troughed at $488000.0 in Q1 2017.
• A 5-year average of $4.2 million and a median of $4.2 million in 2016 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2017 and 2018: Cost of Revenue tumbled 86.17% in 2017, then jumped 264.96% in 2018.
• Over 5 years, Cost of Revenue stood at $5.2 million in 2015, then dropped by 3.0% to $5.1 million in 2016, then sank by 62.68% to $1.9 million in 2017, then soared by 256.12% to $6.8 million in 2018, then decreased by 9.12% to $6.1 million in 2019.
• According to Business Quant data, Cost of Revenue over the past three periods registered $6.1 million, $4.0 million, and $6.0 million for Q4 2019, Q3 2019, and Q2 2019 respectively.